| Rank |
Title |
Year |
PubWeight™‹?› |
|
1
|
Benefits of multidisciplinary teamwork in the management of breast cancer.
|
2013
|
1.08
|
|
2
|
Palbociclib: an evidence-based review of its potential in the treatment of breast cancer.
|
2014
|
1.05
|
|
3
|
Gastric and colon metastasis from breast cancer: case report, review of the literature, and possible underlying mechanisms.
|
2016
|
1.02
|
|
4
|
Multidrug-resistant breast cancer: current perspectives.
|
2014
|
0.99
|
|
5
|
Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer.
|
2014
|
0.97
|
|
6
|
Triple-negative breast cancer: treatment challenges and solutions.
|
2016
|
0.95
|
|
7
|
The incidence rate of female breast cancer in Saudi Arabia: an observational descriptive epidemiological analysis of data from Saudi Cancer Registry 2001-2008.
|
2013
|
0.95
|
|
8
|
Critical analysis of the potential for microRNA biomarkers in breast cancer management.
|
2015
|
0.93
|
|
9
|
p130Cas substrate domain signaling promotes migration, invasion, and survival of estrogen receptor-negative breast cancer cells.
|
2009
|
0.93
|
|
10
|
Current strategies for the prevention of breast cancer.
|
2014
|
0.93
|
|
11
|
Symptom report in detecting breast cancer-related lymphedema.
|
2015
|
0.90
|
|
12
|
Challenges in the development of future treatments for breast cancer stem cells.
|
2010
|
0.89
|
|
13
|
Dormancy in breast cancer.
|
2012
|
0.89
|
|
14
|
Tamoxifen for women at high risk of breast cancer.
|
2014
|
0.89
|
|
15
|
PI3K mutations in breast cancer: prognostic and therapeutic implications.
|
2015
|
0.88
|
|
16
|
Silicone-induced granuloma of breast implant capsule (SIGBIC): similarities and differences with anaplastic large cell lymphoma (ALCL) and their differential diagnosis.
|
2017
|
0.88
|
|
17
|
Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer.
|
2016
|
0.87
|
|
18
|
Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes.
|
2014
|
0.87
|
|
19
|
Current and emerging quantitative magnetic resonance imaging methods for assessing and predicting the response of breast cancer to neoadjuvant therapy.
|
2012
|
0.87
|
|
20
|
Profile of neratinib and its potential in the treatment of breast cancer.
|
2015
|
0.86
|
|
21
|
Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients.
|
2011
|
0.86
|
|
22
|
Epithelial-to-mesenchymal transition in breast cancer: a role for insulin-like growth factor I and insulin-like growth factor-binding protein 3?
|
2015
|
0.85
|
|
23
|
Recent advances in the development of breast cancer vaccines.
|
2014
|
0.85
|
|
24
|
Retracted
Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women.
|
2011
|
0.85
|
|
25
|
Adjuvant systemic therapy in older women with breast cancer.
|
2016
|
0.85
|
|
26
|
EGFR may couple moderate alcohol consumption to increased breast cancer risk.
|
2009
|
0.85
|
|
27
|
Role of the WASP and WAVE family proteins in breast cancer invasion and metastasis.
|
2015
|
0.85
|
|
28
|
Emerging role of brain metastases in the prognosis of breast cancer patients.
|
2011
|
0.84
|
|
29
|
Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system.
|
2016
|
0.84
|
|
30
|
Potential of afatinib in the treatment of patients with HER2-positive breast cancer.
|
2012
|
0.84
|
|
31
|
Keeping an open mind: highlights and controversies of the breast cancer stem cell theory.
|
2012
|
0.84
|
|
32
|
Methods to improve rehabilitation of patients following breast cancer surgery: a review of systematic reviews.
|
2015
|
0.84
|
|
33
|
Patients opting for breast reconstruction following mastectomy: an analysis of uptake rates and benefit.
|
2013
|
0.84
|
|
34
|
Serum calcium levels, TRPM7, TRPC1, microcalcifications, and breast cancer using breast imaging reporting and data system scores.
|
2012
|
0.83
|
|
35
|
In vitro human skin permeation of endoxifen: potential for local transdermal therapy for primary prevention and carcinoma in situ of the breast.
|
2011
|
0.83
|
|
36
|
Optimal management of bone metastases in breast cancer patients.
|
2011
|
0.83
|
|
37
|
Emerging role of cell polarity proteins in breast cancer progression and metastasis.
|
2014
|
0.82
|
|
38
|
Correlation of clinicopathological outcomes with changes in IHC4 status after NACT in locally advanced breast cancers: do pre-NACT ER/PR status act as better prognosticators?
|
2015
|
0.82
|
|
39
|
Development and psychometric testing of a breast cancer patient-profiling questionnaire.
|
2015
|
0.82
|
|
40
|
Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients.
|
2013
|
0.82
|
|
41
|
Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer.
|
2012
|
0.82
|
|
42
|
Contribution of toll-like receptor signaling pathways to breast tumorigenesis and treatment.
|
2013
|
0.81
|
|
43
|
Wortmannin induces MCF-7 breast cancer cell death via the apoptotic pathway, involving chromatin condensation, generation of reactive oxygen species, and membrane blebbing.
|
2012
|
0.81
|
|
44
|
Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer.
|
2011
|
0.81
|
|
45
|
Population-based service mammography screening: the Icelandic experience.
|
2013
|
0.81
|
|
46
|
Lapatinib: new opportunities for management of breast cancer.
|
2010
|
0.81
|
|
47
|
Breast cancer in Brazil: epidemiology and treatment challenges.
|
2015
|
0.81
|
|
48
|
Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women.
|
2011
|
0.80
|
|
49
|
The network of pluripotency, epithelial-mesenchymal transition, and prognosis of breast cancer.
|
2015
|
0.80
|
|
50
|
Identification of genes involved in breast cancer and breast cancer stem cells.
|
2015
|
0.80
|